BACKGROUND: The aim of this study was to investigate the role of pre-treatment aspartate aminotransferase-lynphocyte ratio (ALRI) as a predictor of prognosis and treatment efficacy in patients with metastatic colorectal cancer (mCRC) enrolled in the prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to receive first-line chemotherapy (CT) + bevacizumab (B) or CT alone. PATIENTS AND METHODS: Patients randomly received CT+B or CT alone as first-line therapy. CT consisted of either FOLFOX4 or FOLFIRI at the clinician's discretion. RESULTS: Out of the 284 patients enrolled, increased ALRI levels were associated with shorter PFS and OS (p<0.0001). At baseline, median PFS was 10.3 months (95% CI 9.4-12.0) and 8.0 months (95 % CI 6.8-8.9), and median OS was 25.2 months (95 % CI 21.3-30.2) and 18.8 months (95 % CI 16.6-21.7) for patients with low (<14) and high (≥14) ALRI levels, respectively (HR 1.43, 95% CI 1.12-1.82, p=0.004; HR=1.51, 95% CI 1.17-1.96, p<0.001). Interaction tests on ALRI levels and treatment efficacy in the CT+B and the CT groups were statistically significant for PFS (p=0.0003), but not for OS (p=0.228). CONCLUSION: Our results indicate that ALRI is a good prognostic and predictive marker for mCRC patients candidate for CT+B.
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial / Casadei Gardini, Andrea; Scarpi, Emanuela; Orlandi, Elena; Tassinari, Davide; Leo, Silvana; Bernardini, Ilaria; Gelsomino, Fabio; Tamberi, Stefano; Ruscelli, Silvia; Vespignani, Roberto; Ronconi, Sonia; Frassineti, Giovanni Luca Paolo; Amadori, Dino; Passardi, Alessandro. - In: ONCOTARGETS AND THERAPY. - ISSN 1178-6930. - Volume 11(2018), pp. 5261-5268. [10.2147/OTT.S166614]
Data di pubblicazione: | 2018 | |
Titolo: | Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial | |
Autore/i: | Casadei Gardini, Andrea; Scarpi, Emanuela; Orlandi, Elena; Tassinari, Davide; Leo, Silvana; Bernardini, Ilaria; Gelsomino, Fabio; Tamberi, Stefano; Ruscelli, Silvia; Vespignani, Roberto; Ronconi, Sonia; Frassineti, Giovanni Luca Paolo; Amadori, Dino; Passardi, Alessandro | |
Autore/i UNIMORE: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.2147/OTT.S166614 | |
Rivista: | ||
Volume: | Volume 11 | |
Pagina iniziale: | 5261 | |
Pagina finale: | 5268 | |
Codice identificativo ISI: | WOS:000442917600002 | |
Codice identificativo Scopus: | 2-s2.0-85058699055 | |
Codice identificativo Pubmed: | 30214231 | |
Citazione: | Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial / Casadei Gardini, Andrea; Scarpi, Emanuela; Orlandi, Elena; Tassinari, Davide; Leo, Silvana; Bernardini, Ilaria; Gelsomino, Fabio; Tamberi, Stefano; Ruscelli, Silvia; Vespignani, Roberto; Ronconi, Sonia; Frassineti, Giovanni Luca Paolo; Amadori, Dino; Passardi, Alessandro. - In: ONCOTARGETS AND THERAPY. - ISSN 1178-6930. - Volume 11(2018), pp. 5261-5268. [10.2147/OTT.S166614] | |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer- Results from the randomized ITACa trial.pdf | Versione dell'editore (versione pubblicata) | Open Access Visualizza/Apri |
Pubblicazioni consigliate

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris